The rebranding and SEPA termination are structural, not fundamental, changes. Monitor the U.S. pivotal trial progress for CG-100 and any revenue generation from European commercialization, as these are the key catalysts for the new Eocene platform. The $11.4M cash position provides limited runway for a clinical-stage company with no disclosed revenue.
Price Chart
Executive Summary
Galmed Pharmaceuticals rebranded to Eocene Ltd., changing its Nasdaq ticker to EOCN effective September 10, 2026, and terminated its Standby Equity Purchase Agreement (SEPA) with Yorkville. The SEPA had provided an equity line of up to $20 million, with $7.3 million drawn via 437,947 shares. The rebranding follows the acquisition of Colospan and a strategic pivot toward a GI-focused medtech/biopharma platform, but the filing contains no financial results or guidance, making it a structural update with limited immediate trading impact.
Key Facts
- Company rebranded from Galmed Pharmaceuticals to Eocene Ltd., effective September 10, 2026.
- Nasdaq ticker changed from GLMD to EOCN.
- Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (Yorkville) terminated effective September 8, 2026.
- SEPA provided up to $20 million; $7.3 million was raised through issuance of 437,947 ordinary shares.
- Company regained compliance with Nasdaq minimum bid price rule and will continue listing.
- As of June 30, 2026, the company had $11.4 million in cash, cash equivalents, short-term deposits, and marketable debt securities.
- CG-100 (Colospan) is CE marked in Europe, has FDA Breakthrough Device Designation, and is under an FDA-approved IDE for U.S. pivotal trials.
- Amended and Restated Articles of Association filed as Exhibit 99.2.
Financial Impact
SEPA termination removes a $20M equity line that had $7.3M drawn; $11.4M cash position as of June 30, 2026 provides runway for strategic transition.
Risk Factors
- No disclosed revenue; company is pre-commercial in the U.S. and relies on cash runway for operations.
- CG-100 is not yet approved for commercial use in the U.S.; pivotal trial outcomes are uncertain.
- Limited analyst coverage with 0% bullish consensus suggests low market confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-041872 |
| Exhibit: ex99-1.htm | 0001493152-26-041872 |
| Document: form6-k.htm | 0001493152-26-041872 |
| Document: 0001493152-26-041872-index-headers.html | 0001493152-26-041872 |
| Document: 0001493152-26-041872-index.html | 0001493152-26-041872 |
| Document: 0001493152-26-041872.txt | 0001493152-26-041872 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 6-K | $4.63 $3.63 | ▼ −21.71% | ▼ −21.37% | — |
Sep 4, 2026 7w ago | EFFECT | $3.88 $4.63 | ▼ −19.33% | ▼ −20.54% | — |
Sep 3, 2026 7w ago | 6-K | $3.88 $4.63 | ▲ +19.33% | ▲ +20.54% | — |
Sep 2, 2026 7w ago | 6-K | $3.92 $4.63 | ▲ +18.11% | ▲ +19.26% | — |
Aug 19, 2026 9w ago | 6-K | $4.77 $4.33 | ▼ −9.22% | ▼ −8.84% | — |
Aug 17, 2026 10w ago | 6-K | $0.5134 | awaiting T+5 | — | — |
Jul 28, 2026 12w ago | 6-K | $0.5340 $0.5754 | ▲ +7.75% | ▲ +3.64% | — |
Jul 16, 2026 14w ago | 6-K | $0.5501 $0.5530 | ▲ +0.53% | ▲ +2.20% | — |
Jun 22, 2026 18w ago | 6-K | $0.5641 $0.5709 | ▲ +1.21% | ▲ +1.66% | — |
Jun 8, 2026 20w ago | 6-K | $0.4693 $0.6160 | ▲ +31.26% | ▲ +29.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers